Abiopharma

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Stepan Increases Quarterly Cash Dividend, Marking the 58th Consecutive Year of Increases

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

XORTX Announces Closing of US$1.1 Million Registered Direct Offering

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025